Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
DexCom, Inc. stock logo
DXCM
DexCom
$59.32
-1.2%
$65.87
$54.11
$89.98
$22.89B1.44.90 million shs2.13 million shs
Medtronic PLC stock logo
MDT
Medtronic
$78.06
-0.3%
$88.44
$77.39
$106.33
$100.20B0.628.54 million shs5.53 million shs
7 Stocks to Buy Before SpaceX Goes Public Cover

SpaceX has quietly filed to go public later this year. Ahead of what's expected to be the largest IPO of all time, there are seven space stocks that you can buy today that are positioned to benefit from accelerating space commercialization in 2026.

These seven companies are shaping the next phase of the space economy—from launch leaders and satellite networks to data, defense, and in-space infrastructure.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
DexCom, Inc. stock logo
DXCM
DexCom
0.00%-0.10%-1.40%-14.35%-24.83%
Medtronic PLC stock logo
MDT
Medtronic
0.00%-3.46%-7.61%-22.47%-5.57%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
DexCom, Inc. stock logo
DXCM
DexCom
$59.32
-1.2%
$65.87
$54.11
$89.98
$22.89B1.44.90 million shs2.13 million shs
Medtronic PLC stock logo
MDT
Medtronic
$78.06
-0.3%
$88.44
$77.39
$106.33
$100.20B0.628.54 million shs5.53 million shs
7 Stocks to Buy Before SpaceX Goes Public Cover

SpaceX has quietly filed to go public later this year. Ahead of what's expected to be the largest IPO of all time, there are seven space stocks that you can buy today that are positioned to benefit from accelerating space commercialization in 2026.

These seven companies are shaping the next phase of the space economy—from launch leaders and satellite networks to data, defense, and in-space infrastructure.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
DexCom, Inc. stock logo
DXCM
DexCom
0.00%-0.10%-1.40%-14.35%-24.83%
Medtronic PLC stock logo
MDT
Medtronic
0.00%-3.46%-7.61%-22.47%-5.57%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
DexCom, Inc. stock logo
DXCM
DexCom
2.88
Moderate Buy$83.5040.48% Upside
Medtronic PLC stock logo
MDT
Medtronic
2.58
Moderate Buy$107.8038.57% Upside

Current Analyst Ratings Breakdown

Latest DXCM and MDT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/4/2026
DexCom, Inc. stock logo
DXCM
DexCom
Reiterated RatingBuy$84.00 ➝ $79.00
5/1/2026
DexCom, Inc. stock logo
DXCM
DexCom
Set Price Target$77.00
5/1/2026
DexCom, Inc. stock logo
DXCM
DexCom
Set Price Target$80.00
5/1/2026
DexCom, Inc. stock logo
DXCM
DexCom
Set Price Target$75.00
5/1/2026
DexCom, Inc. stock logo
DXCM
DexCom
Set Price Target$81.00
5/1/2026
DexCom, Inc. stock logo
DXCM
DexCom
Set Price TargetBuy$95.00 ➝ $100.00
5/1/2026
DexCom, Inc. stock logo
DXCM
DexCom
Set Price TargetUnderweight$72.00 ➝ $67.00
5/1/2026
DexCom, Inc. stock logo
DXCM
DexCom
Lower Price TargetBuy$84.00 ➝ $75.00
4/23/2026
Medtronic PLC stock logo
MDT
Medtronic
Reiterated RatingHold$95.00
4/22/2026
Medtronic PLC stock logo
MDT
Medtronic
Lower Price TargetNeutral$104.00 ➝ $90.00
4/21/2026
Medtronic PLC stock logo
MDT
Medtronic
DowngradeBuy (B-)Hold (C+)
(Data available from 5/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
DexCom, Inc. stock logo
DXCM
DexCom
$4.66B4.92$2.68 per share22.16$7.04 per share8.44
Medtronic PLC stock logo
MDT
Medtronic
$33.54B2.98$7.54 per share10.32$37.62 per share2.07
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
DexCom, Inc. stock logo
DXCM
DexCom
$836.30M$2.3425.4219.951.1819.31%33.33%13.19%N/A
Medtronic PLC stock logo
MDT
Medtronic
$4.66B$3.5921.6912.771.9013.00%14.82%7.88%5/20/2026 (Estimated)

Latest DXCM and MDT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/30/2026Q1 2026
DexCom, Inc. stock logo
DXCM
DexCom
$0.47$0.56+$0.09$0.51$1.17 billion$1.19 billion
2/17/2026Q3 2026
Medtronic PLC stock logo
MDT
Medtronic
$1.34$1.36+$0.02$0.89$8.89 billion$9.02 billion
2/12/2026Q4 2025
DexCom, Inc. stock logo
DXCM
DexCom
$0.65$0.68+$0.03$0.68$1.25 billion$1.26 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
DexCom, Inc. stock logo
DXCM
DexCom
N/AN/AN/AN/AN/A
Medtronic PLC stock logo
MDT
Medtronic
$2.843.65%+5.33%79.11%49 Years

Latest DXCM and MDT Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/5/2026
Medtronic PLC stock logo
MDT
Medtronic
quarterly$0.713.26%3/27/20263/27/20264/17/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
DexCom, Inc. stock logo
DXCM
DexCom
0.42
1.95
1.64
Medtronic PLC stock logo
MDT
Medtronic
0.57
2.54
1.87

Institutional Ownership

CompanyInstitutional Ownership
DexCom, Inc. stock logo
DXCM
DexCom
97.75%
Medtronic PLC stock logo
MDT
Medtronic
82.06%

Insider Ownership

CompanyInsider Ownership
DexCom, Inc. stock logo
DXCM
DexCom
0.28%
Medtronic PLC stock logo
MDT
Medtronic
0.26%
CompanyEmployeesShares OutstandingFree FloatOptionable
DexCom, Inc. stock logo
DXCM
DexCom
11,000385.87 million384.79 millionOptionable
Medtronic PLC stock logo
MDT
Medtronic
95,0001.28 billion1.28 billionOptionable

Recent News About These Companies

A Dexcom continuous glucose monitor worn on an arm displays a reading of 108 mg/dL on a paired smartphone app.
3 Reasons Analysts Love DexCom (MDT)
...
Jim Cramer Believes Competitors Might Hurt Intuitive Surgical
Strs Ohio Cuts Holdings in Medtronic PLC $MDT

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
DexCom stock logo

DexCom NASDAQ:DXCM

$59.32 -0.72 (-1.19%)
As of 03:18 PM Eastern
This is a fair market value price provided by Massive. Learn more.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Medtronic stock logo

Medtronic NYSE:MDT

$78.06 -0.24 (-0.30%)
As of 03:18 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.